Simultaneous assay for determining drugs
    1.
    发明授权
    Simultaneous assay for determining drugs 有权
    用于确定药物的同时测定

    公开(公告)号:US07947465B2

    公开(公告)日:2011-05-24

    申请号:US12187661

    申请日:2008-08-07

    IPC分类号: G01N33/00

    摘要: Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.

    摘要翻译: 在同时测定中分析体液中所选择的药物组的药物的存在,其中将流体样品与附加量的所有药物,面板每种药物特异的抗体和微粒 ,将微粒分为子集,面板中每种药物的一个子集,以及与其他子集可区分的每个子集。 孵育在其中发生竞争性结合的液体培养基中进行,样品中的药物与添加到测定培养基中的药物与抗体结合。 在一个程序中,将所添加的药物预先偶联到微粒,而不是抗体,然后孵育后,用对抗体具有亲和性的标记配体进一步孵育微粒。 在替代方法中,所添加的药物不与微粒偶联,而是预先标记,而抗体预偶联于微粒,并且测定在不进一步孵育的情况下进行。 在两种替代方案中,微粒最终从测定培养基和任何未结合物质中回收,并且通过流式细胞术分析回收的微粒,以通过检测标签以相反的方式获得样品中各种药物的存在的迹象 ,每种药物通过微粒的区别特征与其他药物不同。

    Acid catalyzed process
    4.
    发明授权
    Acid catalyzed process 失效
    酸催化过程

    公开(公告)号:US5008468A

    公开(公告)日:1991-04-16

    申请号:US384251

    申请日:1989-08-21

    摘要: This invention provides an improved process for the conversion of reactant into a reaction product, in the presence of a solid acid catalyst comprising sulfonic acid groups covalently bonded to a polymeric chain, wherein the improvement comprises increasing the rate of conversion, on an equivalent sulfonic acid basis, by providing, as said polymeric chain a compound represented by the general formula:M(O.sub.3 ZO.sub.x R).sub.nwherein M is a tetravalent metal ion; Z is a pentavalent atom, selected from the group consisting of elements of Group V of the Periodic Table of the Elements having an atomic weight greater than 30; x varies from 0 to 1; R is select d from the group consisting or organo radicals and mixtures of hydrogen radicals and organo radicals; and n varies from 1 to 2; provided that n is 1 when R is terminated with a tri- or tetraoxy pentavalent atom.

    摘要翻译: 本发明提供了在包含共价键合到聚合物链上的磺酸基团的固体酸催化剂存在下将反应物转化成反应产物的改进方法,其中改进包括增加转化速率等同于磺酸 通过提供作为所述聚合物链的由通式M(O 3 Z x R)n表示的化合物,其中M是四价金属离子; Z是选自原子量大于30的元素周期表第Ⅴ族的元素的五价原子; x从0变化到1; R是选自下组的组或有机基团和氢基团和有机基团的混合物; n从1变化到2; 条件是当R用三或四氧基五价原子封端时n为1。

    High strength plastic furniture dolly
    6.
    发明授权
    High strength plastic furniture dolly 有权
    高强度塑胶家具小车

    公开(公告)号:US08668211B2

    公开(公告)日:2014-03-11

    申请号:US13062337

    申请日:2009-08-28

    申请人: David L. King

    发明人: David L. King

    IPC分类号: B62B5/00

    摘要: A high strength plastic furniture dolly employs a combination of structural features and high strength material to eliminate the need for metal or wood reinforcing elements. The dolly includes first and second longitudinal side members, first and second transverse end members, and caster wheel assemblies mounted longitudinally inward from the transverse end members. The longitudinal side members include a plurality of longitudinally extending parabolic ribs in a central portion and a plurality of non-parabolic ribs in end portions of each side member. The transverse end members include a plurality of transversely extending ribs which may be parabolic.

    摘要翻译: 高强度塑料家具台车采用结构特征和高强度材料的组合,以消除对金属或木材增强元件的需要。 小车包括第一和第二纵向侧构件,第一和第二横向端构件以及从横向端构件纵向向内安装的脚轮组件。 纵向侧构件包括在中心部分中的多个纵向延伸的抛物线肋和在每个侧构件的端部中的多个非抛物线肋。 横向端构件包括可以是抛物线的多个横向延伸的肋。

    Octahedral molecular sieve sorbents and catalysts
    8.
    发明授权
    Octahedral molecular sieve sorbents and catalysts 失效
    八面体分子筛吸附剂和催化剂

    公开(公告)号:US07700517B2

    公开(公告)日:2010-04-20

    申请号:US11347459

    申请日:2006-02-03

    申请人: Liyu Li David L. King

    发明人: Liyu Li David L. King

    IPC分类号: B01J23/34 B01J23/50 B01J20/06

    摘要: Octahedral molecular sieve sorbents and catalysts are disclosed, including silver hollandite and cryptomelane. These materials can be used, for example, to catalyze the oxidation of COx (e.g., CO), NOx (e.g., NO), hydrocarbons (e.g., C3H6) and/or sulfur-containing compounds. The disclosed materials also may be used to catalyze other reactions, such as the reduction of NO2. In some cases, the disclosed materials are capable of sorbing certain products from the reactions they catalyze. Silver hollandite, in particular, can be used to remove a substantial portion of certain sulfur-containing compounds from a gas or liquid by catalysis and/or sorption. The gas or liquid can be, for example, natural gas or a liquid hydrocarbon.

    摘要翻译: 公开了八面体分子筛吸附剂和催化剂,包括银胡萝卜素和cryptomelane。 这些材料可以用于例如催化COx(例如CO),NO x(例如NO),烃(例如C 3 H 6)和/或含硫化合物的氧化。 所公开的材料也可用于催化其它反应,例如还原NO 2。 在一些情况下,所公开的材料能够从它们催化的反应中吸收某些产物。 特别地,银矿砂可以用于通过催化和/或吸附从气体或液体中除去大部分某些含硫化合物。 气体或液体可以是例如天然气或液体烃。

    SIMULTANEOUS ASSAY FOR DETERMINING DRUGS
    9.
    发明申请

    公开(公告)号:US20090053832A1

    公开(公告)日:2009-02-26

    申请号:US11841649

    申请日:2007-08-20

    IPC分类号: G01N33/542

    CPC分类号: G01N33/94 G01N33/54333

    摘要: A method and kits for assaying a sample of a human or mammalian bodily fluid to simultaneously determine whether one or more of a plurality of drugs and/or metabolites thereof are present in said sample and optionally to perform a semi-quantitative assay for said drug or drugs, comprising: (a) incubating the sample in a competitive assay with a plurality of drug conjugates and a plurality of primary antibodies that bind to the drugs whose presence and optionally whose amount is to be determined, wherein either the plurality of drugs or the plurality of primary antibodies is coupled to microparticles comprising magnetically responsive material, the particles being divided into subsets of particles, each distinguishable from the others by one or more differentiation parameters and by the drug to which they are coupled; (b) incubating the product of step (a) with a liquid medium comprising one or more labeled ligands for the primary antibodies or drug conjugates; (c) magnetically separating microparticles in all of said groups from said liquid medium; and defining said liquid medium as a first liquid medium; (d) resuspending said microparticles separated therefrom in a second liquid medium; and (e) analyzing said microparticles in said second liquid medium by flow cytometry and identifying drugs present in the sample, and optionally calculating a semi-quantitative result for drugs found to be present.